Baird has adjusted its rating for HCA Healthcare (HCA, Financial), changing it from Outperform to Neutral. Alongside this downgrade, the firm has also revised its price target for the company's shares, bringing it down to $336 from a previous target of $396.
The decision reflects Baird's assessment of the current market environment for managed care and healthcare facilities. The firm anticipates limited interest from new investors within this sector until uncertainties surrounding policy matters are resolved.
Moreover, Baird does not expect any upward revisions in company guidance, as businesses are likely to adopt a cautious stance for 2025. This conservative approach stems from potential challenges related to Part D and broader economic factors that might surface later in the year.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 21 analysts, the average target price for HCA Healthcare Inc (HCA, Financial) is $373.16 with a high estimate of $438.00 and a low estimate of $317.45. The average target implies an upside of 9.55% from the current price of $340.62. More detailed estimate data can be found on the HCA Healthcare Inc (HCA) Forecast page.
Based on the consensus recommendation from 26 brokerage firms, HCA Healthcare Inc's (HCA, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for HCA Healthcare Inc (HCA, Financial) in one year is $377.88, suggesting a upside of 10.94% from the current price of $340.62. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the HCA Healthcare Inc (HCA) Summary page.
